Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | PNP | P00491 | 6/20 | 0.51 |
| ▸ | QTRT1 | Q9BXR0 | 1/20 | 0.42 |
| ▸ | PI4KA | P42356 | 1/20 | 0.42 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.42 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | TK1 | P04183 | 1/20 | 0.38 |
| ▸ | F7 | P08709 | 1/20 | 0.38 |
| ▸ | F3 | P13726 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21126169 | 0.82 | PNP (0.45) | ALDH1A1PNPQTRT1CYP1A2DYRK1A | |
| SCHEMBL7877139 | 0.81 | PNP (0.49) | ALDH1A1PNPQTRT1CYP1A2DYRK1A | |
| SCHEMBL889723 | 0.81 | CDK4 (0.55) | ALDH1A1CYP1A2PDE2AF7F3 | |
| SCHEMBL12185703 | 0.80 | PNP (0.62) | ALDH1A1PNP | |
| SCHEMBL24097627 | 0.79 | PNP (0.48) | ALDH1A1PNPQTRT1CYP1A2DYRK1A | |
| SCHEMBL8114828 | 0.79 | ALDH1A1 (0.51) | ALDH1A1PNPPI4KAPI4K2BPI4K2A | |
| SCHEMBL13593764 | 0.79 | PI4KA (0.42) | ALDH1A1PNPPI4KAPI4K2BPI4K2A | |
| SCHEMBL3424725 | 0.79 | ALDH1A1 (0.51) | ALDH1A1PDE2AF7F3CDK4 | |
| SCHEMBL15745833 | 0.79 | PDE9A (0.54) | — | |
| SCHEMBL20240237 | 0.78 | ALDH1A1 (0.46) | ALDH1A1PNPPI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4272832-A2 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Lakewood Amedex, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-11795192-B2 | Antimicrobial compounds, compositions, and uses thereof | Lakewood Amedex, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230303613-A1 | 3′3′ CYCLIC DINUCLEOTIDES WITH AN ALKENYLENE | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR, V.V.I. (CZ) | 2023-09-28 | — | — | US | disclosed |
| US-20230303613-A1 | 3′3′ CYCLIC DINUCLEOTIDES WITH AN ALKENYLENE | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR, V.V.I. (CZ) | 2023-09-28 | — | — | US | disclosed |
| US-11766447-B2 | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2023-09-26 | — | — | US | disclosed |
| US-20230212572-A1 | Guanosine Analogues for Use in Therapeutics Polynucleotides | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2023-07-06 | — | — | US | disclosed |
| US-20230212572-A1 | Guanosine Analogues for Use in Therapeutics Polynucleotides | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2023-07-06 | — | — | US | disclosed |
| US-20220152078-A1 | 2'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2022-05-19 | — | — | US | disclosed |
| WO-2021249993-A1 | GUANOSINE ANALOGUES FOR USE IN THERAPEUTIC POLYNUCLEOTIDES | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2021-12-16 | — | — | WO | disclosed |
| EP-3526239-B1 | HIF 1-ALPHA ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORP (KR) | 2021-11-03 | — | — | EP | disclosed |
| US-7556923-B1 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | EPOCH BIOSCIENCES, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7517978-B1 | Modified oligonucleotides and applications thereof | APPLIED BIOSYSTEMS, LLC (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517978-B1 | Modified oligonucleotides and applications thereof | APPLIED BIOSYSTEMS, LLC (US) | 2009-04-14 | — | — | US | disclosed |
| US-20090087922-A1 | SINGLE NUCLEOTIDE POLYMORPHISM ANALYSIS OF HIGHLY POLYMORPHIC TARGET SEQUENCES | EPOCH BIOSCIENCES, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| US-20090048427-A1 | HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS | EPOCH BIOSCIENCES, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-7411065-B2 | Peptide nucleic acid monomers: diphenylmethyl, benzyl, alkylthioalkyl, or phenylthioalkyl esters of N-(1-[4-(2-benzothiazolyl-, 2-benzoxazolyl-, 2-benzofuranyl- or 2-benzothiophenyl-sulfonyl)-3-piperazinon-1-ylcarbonylmethyl]pyrimidon-4-yl)carbamic acids | PANAGENE, INC. (KR) | 2008-08-12 | — | — | US | disclosed |
| US-7371860-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2008-05-13 | — | — | US | disclosed |
| US-7348146-B2 | Single nucleotide polymorphism analysis of highly polymorphic target sequences | EPOCH BIOSCIENCES, INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-7211668-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2007-05-01 | — | — | US | disclosed |
| US-7179896-B2 | Method of making PNA oligomers | PANAGENE, INC. (KR) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11766447-B2 | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator | STING1, MAVS, CGAS | ALDH1A1 4803/4885PNP 220/4885QTRT1 3599/4885 |
| US-20090048427-A1 | HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS | DDB1, LIG3, MSH2 | ALDH1A1 4598/4885PNP 3801/4885QTRT1 2426/4885 |
| US-20220152078-A1 | 2'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF | STING1, CGAS, NT5C2 | ALDH1A1 3369/4885PNP 9/4885QTRT1 2184/4885 |
| US-11795192-B2 | Antimicrobial compounds, compositions, and uses thereof | CAT, MPO, NISCH | ALDH1A1 2110/4885PNP 848/4885QTRT1 1769/4885 |
| US-20230303613-A1 | 3′3′ CYCLIC DINUCLEOTIDES WITH AN ALKENYLENE | STING1, CGAS, IRF3 | ALDH1A1 3968/4885PNP 47/4885QTRT1 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.